Revenio Group Corporation to transfer shares related to the share-based awards to CEO

The Board of Directors of Revenio Group Corporation decided, on February 13, 2023, on the basis of the share issue authorization granted to the Board of Directors by the company's Annual General Meeting held on April 8, 2022, to issue shares, altogether 400 Revenio Group Corporation shares held by the company, in a directed free share issue to CEO Jouni Toijala for the payment of share-based award under the 2021-2023 LTI RS-program from year 2022.

The shares to be issued in the free directed share issue will be issued in accordance with the terms of the company's current share-based incentive plan, which will improve CEO`s permanence and work motivation, so there is a particularly weighty financial reason under the Companies Act (9:4.1). The key terms of the share-based incentive plan are described in the company's 2021 Remuneration Report.

After the transfer, the company holds 92,218 treasury shares.

Revenio Group Corporation
Board of Directors

For further information, please contact
CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution
Nasdaq Helsinki Ltd
Main media
www.revenio.fi

Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2022, the Group’s net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.